NeoImmuneTech said on the 11th that it has obtained the approval for a phase 2 clinical trial plan that concomitant administration of U.S. Merck’s immune checkpoint inhibitor Keytruda and its T-cell amplifier NT-I7 to patients with glioblastoma from the U.S. FDA.
The phase 2 trial will be led by Professor Jian Campian at the U.S. Mayo Clinic. It will evaluate the safety and treatment efficacy. Merck and NeoImmuneTech will supply Keytruda and NT-I7.
The research team expects the concomitant administration of Keytruda and NT-I7 to improve the survival rate of patients with glioblastoma.
The survival time of glioblastoma is less than 6 months, and the prognosis is very poor. Some chemotherapy drugs and a target anticancer Avastin are used for treatment, but the effectiveness is not significant. Genexine is conducting a clinical trial of the concomitant administration of Avastin and Efineptakin Alfa (GX-I7) in Korea, and NeoImmuneTech plans to test immune checkpoint inhibitor and T-cell amplifier. After the phase 2 trial, it will enter the phase 3 trial of the most likely treatment.
NT-I7 is a drug that amplifies T cell immunity to remove cancer cells and infected cells. Currently, it is under the clinical development to treat various deadliest cancers and infectious diseases.
By Global Economic Reporter Do-yeol Lee ; Translate by Gounee Yang